Competition Government Pharmaceutical manufacturing 
European Pharmaceutical Review
JULY 15, 2022
The four governments of the UK established the scheme to increase the climate ambition of the UK’s carbon pricing policy, whilst also protecting the competitiveness of UK businesses. The post Sustainable energy strategies for pharmaceutical manufacturers appeared first on European Pharmaceutical Review.
European Pharmaceutical Review
AUGUST 29, 2024
A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The post Innovative pharma-government partnership to enhance UK clinical trials appeared first on European Pharmaceutical Review.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 24, 2023
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Since 2010, the UK has fallen from 4th to 98th place in overall trade balance in pharmaceuticals, due to fierce global competition, according to the MMIP.
European Pharmaceutical Review
SEPTEMBER 29, 2022
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.
pharmaphorum
NOVEMBER 25, 2022
Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society. The challenge facing the pharmaceutical industry today though, he said, is to go beyond the standards of care, and improve drugs to make them safer and more effective. The situation was reversed only 25 years ago.
Pharmaceutical Technology
JULY 29, 2022
This is borne out of the fact that while nearly three-quarters are confident in the education and training for those in the pharma sector, just 64% are confident with the industry’s ability to source engineers against competition from other sectors. Manufacturing agility: Index score 6.5/10.
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Policy and Payer Developments Historically, we have seen that government and regulatory decisions can often have a major impact on the adoption of biosimilars.
Expert insights. Personalized for you.
105 
Let's personalize your content